(E)-4-(2-(4-bromobenzylthio)-3-(3-fluoro-4-nitrophenyl)acryloyl)benzoic acid | 1224721-89-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: (E)-4-(2-(4-bromobenzylthio)-3-(3-fluoro-4-nitrophenyl)acryloyl)benzoic acid
• 英文别名: (E)-4-(2-(4-Bromobenzylthio)-3-(3-fluoro-4-nitrophenyl)-acryloyl)benzoic acid；4-[(E)-2-[(4-bromophenyl)methylsulfanyl]-3-(3-fluoro-4-nitrophenyl)prop-2-enoyl]benzoic acid
• CAS: 1224721-89-4
• 化学式: C₂₃H₁₅BrFNO₅S
• 分子量: 516.344
• InChiKey: FIQGSMLCAHEYSC-CIAFOILYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-(2-(4-bromobenzylthio)acetyl)benzoic acid 、 3-氟-4-硝基苯甲醛 在 ammonium acetate 、 溶剂黄146 作用下， 以90%的产率得到(E)-4-(2-(4-bromobenzylthio)-3-(3-fluoro-4-nitrophenyl)acryloyl)benzoic acid
  参考文献：
  名称：

  Design, synthesis and evaluation of (E)-α-benzylthio chalcones as novel inhibitors of BCR-ABL kinase

  摘要：

  Novel (E)-alpha-benzylthio chalcones are reported with preliminary in vitro activity data indicating that several of them are potent inhibitors (comparable to imatinib, the reference compound) of BCR-ABL phosphorylation in leukemic K562 cells, known to express high levels of BCR-ABL. The ability of such compounds to significantly inhibit K562 cell proliferation suggests that this scaffold could be a promising lead for the development of anticancer agents that are able to block BCR-ABL phosphorylation in leukemic cells. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.01.051

文献信息

• Design, synthesis and evaluation of (E)-α-benzylthio chalcones as novel inhibitors of BCR-ABL kinase
  作者：M.V. Ramana Reddy、Venkat R. Pallela、Stephen C. Cosenza、Muralidhar R. Mallireddigari、Revathi Patti、Marie Bonagura、May Truongcao、Balaiah Akula、Shashidhar S. Jatiani、E. Premkumar Reddy

  DOI：10.1016/j.bmc.2010.01.051

  日期：2010.3

  Novel (E)-alpha-benzylthio chalcones are reported with preliminary in vitro activity data indicating that several of them are potent inhibitors (comparable to imatinib, the reference compound) of BCR-ABL phosphorylation in leukemic K562 cells, known to express high levels of BCR-ABL. The ability of such compounds to significantly inhibit K562 cell proliferation suggests that this scaffold could be a promising lead for the development of anticancer agents that are able to block BCR-ABL phosphorylation in leukemic cells. (C) 2010 Elsevier Ltd. All rights reserved.